Factors Associated With Altmetric Attention Scores for Randomized Phase III Cancer Clinical Trials

被引:0
|
作者
Rooney, Michael K. [1 ]
Sharifi, Bahareh [1 ]
Ludmir, Ethan B. [1 ]
Fuller, Clifton D. [1 ]
Warner, Jeremy L. [2 ,3 ,4 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX USA
[2] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA
[3] Lifespan Canc Inst, Providence, RI USA
[4] Brown Univ, 231 Elmgrove Ave,PRB 777, Providence, RI 02906 USA
来源
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Altmetric Attention Scores (Altmetrics) are real-time measures of scientific impact and attention through various public outlets, including news, blogs, and social media. Herein, we aimed to describe and characterize the relationship between Altmetrics, conventional impact metrics, and features of published cancer clinical trials.METHODS We identified two-arm phase III cancer randomized clinical trials with a superiority end point and publication date between 2015 and 2020 from HemOnc and tabulated the following data: Altmetric, study positivity, US Food and Drug Administration (FDA) registration trial status, cancer site/category, treatment context (curative or palliative), trial design, primary end point type, experimental/control arm modality, and journal tier. We further collected conventional bibliometrics including the number of citations and relative citation ratio (RCR) for all published studies. Multiple linear regression modeling identified clinical trial factors predictive of Altmetrics, with alpha = .05 defining statistical significance.RESULTS Altmetrics were found for 681 (98%) of 698 publications, with a median score of 38.5 (IQR, 13-132.8). FDA registration studies (beta [95% CI], 84.7 [48.8 to 120.6]; P < .001), studies reporting on curative (as opposed to palliative) interventions (-29 [-53.7 to -4.4]; P = .02), genitourinary trials (73.2 [28.1 to 118.2]; P = .001), studies published in tier 1 journals (P < .001), and those with an increased number of citations per year (0.81 [0.66 to 0.95]; P < .001) were significantly associated with increased engagement as measured by Altmetrics. Furthermore, there was a strong correlation between all collected bibliometrics and Altmetrics (R2 = 0.63, 0.68, and 0.67; P < .001 for citation count, citations per year, and RCR, respectively).CONCLUSION FDA registration trials describing curative interventions, studies published in traditionally defined high-impact journals, and genitourinary trial publications tend to have the greatest Altmetrics. We observed a strong relationship between Altmetrics and conventional bibliometrics. The significance and consequences of these relationships warrant further investigation.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Factors Associated With Altmetric Attention Scores for Randomized Phase III Cancer Clinical Trials
    Rooney, Michael K.
    Sharifi, Bahareh
    Ludmir, Ethan B.
    Fuller, Clifton D.
    Warner, Jeremy L.
    [J]. JCO CLINICAL CANCER INFORMATICS, 2023, 7
  • [2] Factors associated with altmetric attention scores for randomized phase III cancer clinical trials.
    Rooney, Michael Kevin
    Ludmir, Ethan B.
    Fuller, Clifton Dave
    Warner, Jeremy Lyle
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Orthopaedic Randomized Controlled Trials Published in General Medical Journals Are Associated With Higher Altmetric Attention Scores and Social Media Attention Than Nonorthopaedic Randomized Controlled Trials
    Polce, Evan M. Y. Y.
    Kunze, Kyle N.
    Farivar, Daniel
    Fu, Michael C.
    Nwachukwu, Benedict U.
    Nho, Shane J.
    Chahla, Jorge
    [J]. ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY, 2021, 37 (04): : 1261 - 1270
  • [4] Factors associated with publication of randomized phase III cancer trials in journals with a high impact factor
    Tang, P. A.
    Pond, G. R.
    Welch, S.
    Chen, E. X.
    [J]. CURRENT ONCOLOGY, 2014, 21 (04) : E564 - E572
  • [5] Exclusion of Men from Randomized Phase III Breast Cancer Clinical Trials
    Corrigan, Kelsey L.
    Mainwaring, Walker
    Miller, Austin B.
    Lin, Timothy A.
    Jethanandani, Amit
    Espinoza, Andres F.
    Piotrowski, Matt
    Fuller, C. David
    Stauder, Michael C.
    Shaitelman, Simona F.
    Perkins, George H.
    Woodward, Wendy A.
    Giordano, Sharon H.
    Smith, Benjamin D.
    Ludmir, Ethan B.
    [J]. ONCOLOGIST, 2020, 25 (06): : E990 - E992
  • [6] Graphical abstracts are associated with greater Altmetric attention scores, but not citations, in sport science
    Hunter Bennett
    Flynn Slattery
    [J]. Scientometrics, 2023, 128 : 3793 - 3804
  • [7] Graphical abstracts are associated with greater Altmetric attention scores, but not citations, in sport science
    Bennett, Hunter
    Slattery, Flynn
    [J]. SCIENTOMETRICS, 2023, 128 (06) : 3793 - 3804
  • [8] Current randomized phase III trials in gynecologic cancer
    不详
    [J]. ONCOLOGY-NEW YORK, 2004, 18 (13): : 1642 - +
  • [9] Factors associated with high Altmetric Attention Score in dermatology research
    Iglesias-Puzas, Alvaro
    Conde-Taboada, Alberto
    Aranegui-Arteaga, Beatriz
    Lopez-Bran, Eduardo
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 (03) : E380 - E385
  • [10] Control of false positives in randomized phase III clinical trials
    Shen, Changyu
    Liu, Ziyue
    Xu, Huiping
    Liu, Hai
    Yue, Cynthia
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2017, 27 (05) : 719 - 731